Welcome to the Arvinas fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to turn the conference over ...

Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data ...

Pharmaengine Inc. and Sentinel Oncology Ltd. have synthesized Wee1-like protein kinase (Wee1) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of ...

Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Arvinas Inc. (NASDAQ:ARVN), a biotechnology company specializing in protein degradation therapeutics, stands at a critical juncture as it approaches the release of pivotal clinical trial data.

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage.

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

The best protein shakers are a must-buy, so we've tried and tested the best on the market to help you decide what to carry before, during and after your workouts. And we've done that much testing ...

Live your life healthier and happier with our free weekly Living Well newsletter As one of the three main macronutrients (along with fat and carbohydrates), protein is essential for promoting ...